Phase 2 Study of Atezolizumab With or Without Entinostat in Patie

Phase 1b (Dose Determination Cohort): To determine the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of entinostat (SNDX-275) given in combination with atezolizumab. Phase 2 (Expansion Cohort): To perform an evaluation of the efficacy of entinostat at the RP2D in combination with atezolizumab in patients with aTNBC, as determined by the duration of progression-free survival (PFS) based on the local investigator’s assessment of progressive disease using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) .

July 03, 2017